Teclistamab in Multiple Myeloma: Mechanism, Structure and Clinical Trial Results
Teclistamab is a BCMA × CD3 bispecific antibody that redirects T cells to kill multiple myeloma cells in relapsed patients. Read more
Tag: bispecific antibodies
BCMA-Targeted Therapies in Multiple Myeloma: Teclistamab vs CAR-T vs Antibody-Drug Conjugates
Compare BCMA therapies in multiple myeloma including Teclistamab, CAR-T therapy, and antibody-drug conjugates with mechanisms and clinical outcomes. Read more
BCMA Signaling Pathway in Multiple Myeloma: Structure, Function and Therapeutic Targeting
BCMA signaling drives plasma cell survival in multiple myeloma through BAFF/APRIL activation of NF-κB, PI3K-AKT, and MAPK pathways. Read more